NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include mogamulizumab (POTELIGEO) as a preferred treatment option for stages IB MF to IVA2 SS1
In stages:
- IB-IIA MF
- IIB MF—Limited tumor disease
- IIB MF—Generalized tumor disease
- III MF—Erythrodermic disease
- IVA1 SS
- IVA2 SS
In stages:
- IVA2—Non-Sézary
- IVB—Visceral/solid organ disease
NCCN Guidelines® state that the goals of therapy for Mycosis Fungoides and Sézary Syndrome should be individualized but often include1:
- Minimizing risk of disease progression
- Attaining symptom control
- Minimizing risk of adverse effects
- Absence of cumulative toxicity
Most treatments do not result in durable remissions off of treatment. Other than allogeneic HCT, therapies are not given with curative intent.1
Generally, skin-directed therapies and systemic therapy regimens that can be tolerated for longer durations with lower rates of cumulative toxicity, less immunosuppression, and/or higher efficacy are used in earlier lines of therapy.1
Therapies with lower side-effect profiles and an absence of cumulative toxicity are often given in an ongoing or maintenance fashion to improve and maintain disease control and quality of life.1
- aNCCN recommends systemic therapies in combination with skin-directed therapies in select cases. There is limited safety data for the use of TSEBT in combination with mogamulizumab.1
- NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- HCT=hematopoietic stem cell transplant; NCCN=National Comprehensive Cancer Network®; TSEBT=total skin electron beam therapy
Continue exploring why POTELIGEO is a preferred treatment option
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Primary Cutaneous Lymphomas V.1.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 11, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.